Tags

Type your tag names separated by a space and hit enter

Controlled clinical trial of pentoxifylline versus cinnarizine in the treatment of labyrinthine disorders.
Pharmatherapeutica. 1988; 5(3):170-6.P

Abstract

Seventy-six patients with labyrinthine diseases of vascular origin were treated in a 6-week double-blind comparative study with either 400 mg pentoxifylline ('Trental') or 75 mg cinnarizine 3-times daily. Clinical evaluations, supported by audiological tests and vectornystagmography, were carried out before and after treatment. Statistical analysis of the results showed pentoxifylline to be globally superior to cinnarizine and especially to have a more intense antivertiginous effect. No significant differences were observed between the two drugs in respect of tinnitus and hearing loss therapy. Side-effects were occasional, mild and well tolerated in the pentoxifylline group, and more pronounced and frequent with cinnarizine.

Authors+Show Affiliations

Department of Otorhinolaryngology, Escola Paulista de Medicina, São Paulo, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3283777

Citation

Ganança, M M., et al. "Controlled Clinical Trial of Pentoxifylline Versus Cinnarizine in the Treatment of Labyrinthine Disorders." Pharmatherapeutica, vol. 5, no. 3, 1988, pp. 170-6.
Ganança MM, Mangabeira Albernaz PL, Caovilla HH, et al. Controlled clinical trial of pentoxifylline versus cinnarizine in the treatment of labyrinthine disorders. Pharmatherapeutica. 1988;5(3):170-6.
Ganança, M. M., Mangabeira Albernaz, P. L., Caovilla, H. H., & Ito, Y. I. (1988). Controlled clinical trial of pentoxifylline versus cinnarizine in the treatment of labyrinthine disorders. Pharmatherapeutica, 5(3), 170-6.
Ganança MM, et al. Controlled Clinical Trial of Pentoxifylline Versus Cinnarizine in the Treatment of Labyrinthine Disorders. Pharmatherapeutica. 1988;5(3):170-6. PubMed PMID: 3283777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Controlled clinical trial of pentoxifylline versus cinnarizine in the treatment of labyrinthine disorders. AU - Ganança,M M, AU - Mangabeira Albernaz,P L, AU - Caovilla,H H, AU - Ito,Y I, PY - 1988/1/1/pubmed PY - 1988/1/1/medline PY - 1988/1/1/entrez SP - 170 EP - 6 JF - Pharmatherapeutica JO - Pharmatherapeutica VL - 5 IS - 3 N2 - Seventy-six patients with labyrinthine diseases of vascular origin were treated in a 6-week double-blind comparative study with either 400 mg pentoxifylline ('Trental') or 75 mg cinnarizine 3-times daily. Clinical evaluations, supported by audiological tests and vectornystagmography, were carried out before and after treatment. Statistical analysis of the results showed pentoxifylline to be globally superior to cinnarizine and especially to have a more intense antivertiginous effect. No significant differences were observed between the two drugs in respect of tinnitus and hearing loss therapy. Side-effects were occasional, mild and well tolerated in the pentoxifylline group, and more pronounced and frequent with cinnarizine. SN - 0308-051X UR - https://www.unboundmedicine.com/medline/citation/3283777/Controlled_clinical_trial_of_pentoxifylline_versus_cinnarizine_in_the_treatment_of_labyrinthine_disorders_ DB - PRIME DP - Unbound Medicine ER -